einstein (São Paulo). 04/Sep/2019;17(4):eAO4742.

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

Emanuel Almeida Moreira de Oliveira ORCID logo , Kenia de Assis Boy ORCID logo , Ana Paula Pinho Santos ORCID logo , Carla da Silva Machado ORCID logo , Cibele Velloso-Rodrigues ORCID logo , Pâmela Souza Almeida Silva Gerheim ORCID logo , Leonardo Meneghin Mendonça ORCID logo

DOI: 10.31744/einstein_journal/2019AO4742

ABSTRACT

Objective

To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.

Methods

The study subjects were divided into two groups: one group of 22 patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea, and a Control Group composed of 24 patients with sickle cell disease who were not treated with hydroxyurea. Peripheral blood samples were submitted to peripheral blood mononuclear cell isolation to assess genotoxicity by the cytokinesis-block micronucleus cytome assay, in which DNA damage biomarkers – micronuclei, nucleoplasmic bridges and nuclear buds – were counted.

Results

Patients with sickle cell disease treated with hydroxyurea had a mean age of 25.4 years, whereas patients with sickle cell disease not treated with hydroxyurea had a mean age of 17.6 years. The mean dose of hydroxyurea used by the patients was 12.8mg/kg/day, for a mean period of 44 months. The mean micronucleus frequency per 1,000 cells of 8.591±1.568 was observed in the Hydroxyurea Group and 10.040±1.003 in the Control Group. The mean frequency of nucleoplasmic bridges per 1,000 cells and nuclear buds per 1,000 cells for the hydroxyurea and Control Groups were 0.4545±0.1707 versus 0.5833±0.2078, and 0.8182±0.2430 versus 0.9583±0.1853, respectively. There was no statistically significant difference between groups.

Conclusion

In the study population, patients with sickle cell disease treated with the standard dose of hydroxyurea treatment did not show evidence of DNA damage induction.

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

Comments